Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CTH | P32929 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13380943 | 0.87 | SMN1; SMN2 (0.63) | SMN1; SMN2MEN1KMT2AL3MBTL1CTH | |
| Nicothiazone SCHEMBL2110572 | 0.84 | CTH (0.67) | SMN1; SMN2MEN1KMT2AL3MBTL1CTH | |
| Nicothiazone SCHEMBL27963917 | 0.84 | CTH (0.67) | SMN1; SMN2MEN1KMT2AL3MBTL1CTH | |
| SCHEMBL8011652 | 0.80 | SMN1; SMN2 (0.72) | SMN1; SMN2MEN1KMT2AL3MBTL1CTH | |
| SCHEMBL8011653 | 0.80 | SMN1; SMN2 (0.72) | SMN1; SMN2MEN1KMT2AL3MBTL1CTH | |
| SCHEMBL4100494 | 0.80 | CTH (0.54) | SMN1; SMN2MEN1KMT2AL3MBTL1CTH | |
| SCHEMBL4100496 | 0.80 | CTH (0.54) | SMN1; SMN2MEN1KMT2AL3MBTL1CTH | |
| SCHEMBL924522 | 0.79 | MEN1 (0.60) | SMN1; SMN2MEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL914606 | 0.79 | MEN1 (0.60) | SMN1; SMN2MEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL9134788 | 0.79 | KMT2A (0.73) | SMN1; SMN2MEN1KMT2AL3MBTL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220015367-A1 | SELF-ASSEMBLED ACTIVE AGENTS | METHODS PRODUCTS PBC | 2022-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220015367-A1 | SELF-ASSEMBLED ACTIVE AGENTS | PCNA, POLM, MUS81 | SMN1; SMN2 4332/4885MEN1 2860/4885KMT2A 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.